

## **Lysando Welcomes Healthcare Investment Strategist Deborah Fleischer to its Advisory Board**

**TRIESENBERG, Liechtenstein, May 21, 2024** – Lysando AG, a leading biopharmaceutical innovator specializing in antimicrobial solutions, is pleased to announce the appointment of Deborah Fleischer as a new Advisory Board member. In her role, Deborah will provide strategic guidance and invaluable insights to Lysando’s leadership team, drawing on her extensive experience in the investment and healthcare sectors.

Deborah Fleischer brings unique expertise to her new position. Currently working as an investment professional at a global investment firm, she is mainly involved in deal making within the pharma and life sciences sector. Previously, Deborah held the position of board observer at Galderma, a renowned player in the dermatology sector, where she played a pivotal role in its successful IPO on the Swiss Stock Exchange (SIX) in March 2024. The IPO, which values Galderma at approximately CHF 15 billion (USD 17 billion), represents the largest IPO placement in Switzerland since 2017 and will likely to be one of the biggest in Europe this year. Prior to joining her current employer, Deborah has paved her career path for three years at another investment firm based out of Frankfurt. Her successful career began in investment banking at a leading bank in Paris after having achieved her master’s degree in Management from the University of Mannheim and ESSEC Business School.

“Coupled with Deborah’s deep understanding of both investment strategies and the healthcare landscape, her diverse background enriches our strategic discussion making, and will provide invaluable guidance,” says Count Markus Matuschka de Greiffenclau, Chairman of the Board of Directors of Lysando AG. “Deborah’s presence on our Advisory Board marks an exciting chapter in our journey towards advancing patient care and making a meaningful difference in patients’ lives.”

Commenting on her new role, Deborah Fleischer stated: “I am excited about the tremendous potential of Lysando’s platform technology, Artilysin®, in fighting antimicrobial resistance and its proven capacity to enhance patient outcomes already today.”

Join us in welcoming Deborah Fleischer to Lysando AG’s Advisory Board and learn more about our innovative antimicrobial solutions powered by Artilysin® technology. For further information about Lysando AG and our commitment to advancing patient care, visit our website or contact us directly.

### **About Lysando AG**

Lysando AG is market leader for antimicrobial proteins, Artilysin® molecules, which can effectively eliminate problem-causing bacteria without associated high risk of resistance formation and microbial disbalances. Artilysin® constitutes an innovative, proprietary, and environmentally friendly technology with a wide range of applications.